Yes. Cyproheptadine is a prescription medication, so carry the original prescription label and a copy of the prescription. Present it to security personnel if asked.
In the UK the 4 mg tablets are typically round, white or off-white, and may bear the imprint “CPH 4 mg” (imprint codes can vary by manufacturer).
Alcohol can increase the sedative and anticholinergic effects of cyproheptadine, leading to heightened drowsiness and impaired coordination. It is advisable to limit or avoid alcohol while taking the medication.
Because cyproheptadine commonly causes drowsiness, you should not drive or operate machinery until you know how the drug affects you, especially during the first few days of therapy.
Cyproheptadine is classified as pregnancy category C in the UK, meaning it should only be used when the potential benefit justifies any possible risk to the fetus. Pregnant women must discuss alternatives with their obstetrician.
The drug stimulates appetite by antagonising serotonin receptors that normally suppress hunger, and its antihistamine action can also increase appetite. This effect is leveraged off-label to treat weight loss in certain medical conditions.
Cyproheptadine is a first-generation antihistamine that crosses the blood-brain barrier, producing sedation and anticholinergic effects. Newer second-generation agents such as cetirizine are more selective for peripheral H₁ receptors and cause far less drowsiness.
Onset of action usually occurs within 30 minutes, with peak effect around 2 hours after ingestion. Full symptom control may require several days of regular dosing.
Take the missed dose as soon as you remember, unless the next scheduled dose is due within a few hours. In that case, skip the missed dose and continue with your regular dosing schedule-do not double the dose.
Shelf-life varies by manufacturer but is typically 2-3 years from the date of manufacture. Always check the expiry date on the packaging and discard any tablets that are past that date.
Cyproheptadine is a first-generation antihistamine that is also a serotonin (5-HT₂) antagonist. It is supplied as a 4 mg oral pill and is classified in the United Kingdom as a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The medication is known for two primary therapeutic roles: relief of allergy-related symptoms and stimulation of appetite in certain patient groups.
Cyproheptadine blocks the histamine H₁ receptors that mediate the classic signs of an allergic reaction-itching, swelling, and watery secretions. By preventing histamine from binding, it reduces vasodilation and capillary permeability, which eases rash, urticaria, and nasal congestion.
In addition, cyproheptadine antagonises serotonin 5-HT₂ receptors. This action dampens serotonergic activity in the central nervous system, which contributes to its usefulness in conditions such as serotonin syndrome and some migraine-related pathways. The drug also exhibits anticholinergic and antihistaminic activity at other receptor sites, accounting for its sedative and appetite-stimulating effects.
These indications are recognised by the MHRA and are the basis for routine prescribing in primary and secondary care in the UK.
Off-label use requires medical supervision and an individualized risk-benefit assessment.
Absolute contraindications
Known hypersensitivity to cyproheptadine or any of its excipients.
Narrow-angle glaucoma or severe obstructive uropathy (e.g., prostatic hypertrophy) due to anticholinergic effects.
Relative contraindications / cautions
Pregnancy - Category C; use only if the expected benefit outweighs potential risk.
Breast-feeding - Small amounts are excreted in milk; caution advised.
Elderly patients - Higher susceptibility to sedation, confusion, and falls.
Severe hepatic impairment - Reduced metabolism may increase systemic exposure; dose reduction recommended.
Asthma - May exacerbate bronchospasm in susceptible individuals.
Patients with any of the above conditions should discuss alternatives with their prescriber.
These effects are usually transient and lessen with continued therapy.
If any of these occur, seek immediate medical attention.
Patients are encouraged to disclose all concurrent medicines, supplements, and herbal products to their healthcare provider.
Dosing must be individualized; the prescriber may adjust the regimen based on age, liver function, and therapeutic response.
This article provides educational information about cyproheptadine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
